Kymera Therapeutics, Inc.·4

Jun 11, 4:47 PM ET

Ridloff Elena 4

4 · Kymera Therapeutics, Inc. · Filed Jun 11, 2025

Insider Transaction Report

Form 4
Period: 2025-06-11
Transactions
  • Sale

    Common Stock

    2025-06-11$50.00/sh4,500$225,0000 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-06-114,5004,500 total
    Exercise: $20.29Exp: 2032-06-29Common Stock (4,500 underlying)
  • Exercise/Conversion

    Common Stock

    2025-06-11$20.29/sh+4,500$91,3054,500 total
Footnotes (2)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person.
  • [F2]The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following the vesting commencement date of June 29, 2022, subject to the reporting person's continued service relationship through each vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4